New technologies including gene-expression profiling has increased the list of candidate tumor antigens. Investigators have focused on targets which are either tumourspecific, including idiotypic antigens of B-cell tumours [11] or tumour-associated antigens [12] that are also expressed by the normal cell of origin [13] and that include the so-called cancer-testis antigens [14] .